CARIOU Bertrand
CARIOU Bertrand
CHU Nantes
Verified email at
Cited by
Cited by
Role of bile acids and bile acid receptors in metabolic regulation
P Lefebvre, B Cariou, F Lien, F Kuipers, B Staels
Physiological reviews 89 (1), 147-191, 2009
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ...
The Lancet 385 (9965), 331-340, 2015
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
JF Yale, G Bakris, B Cariou, D Yue, E David‐Neto, L Xi, K Figueroa, ...
Diabetes, Obesity and Metabolism 15 (5), 463-473, 2013
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
B Cariou, K van Harmelen, D Duran-Sandoval, TH van Dijk, A Grefhorst, ...
Journal of Biological Chemistry 281 (16), 11039-11049, 2006
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY …
CP Cannon, B Cariou, D Blom, JM McKenney, C Lorenzato, R Pordy, ...
European heart journal 36 (19), 1186-1194, 2015
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)
B Zinman, A Philis-Tsimikas, B Cariou, Y Handelsman, HW Rodbard, ...
Diabetes care 35 (12), 2464-2471, 2012
Thiazolidinediones and PPARγ agonists: time for a reassessment
B Cariou, B Charbonnel, B Staels
Trends in Endocrinology & Metabolism 23 (5), 205-215, 2012
Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic …
B Staels, A Rubenstrunk, B Noel, G Rigou, P Delataille, LJ Millatt, ...
Hepatology 58 (6), 1941-1952, 2013
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet, B Cariou, G Lambert, F Lalanne, B Lardeux, AL Jarnoux, ...
Journal of Biological Chemistry 281 (10), 6211-6218, 2006
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ...
The lancet Diabetes & endocrinology 5 (2), 97-105, 2017
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity
J Prawitt, M Abdelkarim, JHM Stroeve, I Popescu, H Duez, VR Velagapudi, ...
Diabetes 60 (7), 1861-1871, 2011
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition
D Duran-Sandoval, B Cariou, F Percevault, N Hennuyer, A Grefhorst, ...
Journal of Biological Chemistry 280 (33), 29971-29979, 2005
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
JF Yale, G Bakris, B Cariou, J Nieto, E David‐Neto, D Yue, E Wajs, ...
Diabetes, Obesity and Metabolism 16 (10), 1016-1027, 2014
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised …
P Dandona, C Mathieu, M Phillip, L Hansen, SC Griffen, D Tschöpe, ...
The lancet Diabetes & endocrinology 5 (11), 864-876, 2017
Dual Peroxisome Proliferator–Activated Receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects
B Cariou, R Hanf, S Lambert-Porcheron, Y Zaïr, V Sauvinet, B Noël, L Flet, ...
Diabetes care 36 (10), 2923-2930, 2013
Effects of the new dual PPARα/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism
B Cariou, Y Zaïr, B Staels, E Bruckert
Diabetes Care 34 (9), 2008-2014, 2011
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study
B Cariou, S Hadjadj, M Wargny, M Pichelin, A Al-Salameh, I Allix, ...
Diabetologia, 1-16, 2020
Clinical aspects of PCSK9
B Cariou, C Le May, P Costet
Atherosclerosis 216 (2), 258-265, 2011
Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia
C Le May, S Kourimate, C Langhi, M Chétiveaux, A Jarry, C Comera, ...
Arteriosclerosis, thrombosis, and vascular biology 29 (5), 684-690, 2009
Peroxisome proliferator–activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties
E Teissier, A Nohara, G Chinetti, R Paumelle, B Cariou, JC Fruchart, ...
Circulation research 95 (12), 1174-1182, 2004
The system can't perform the operation now. Try again later.
Articles 1–20